At UC Berkeley Dr. Johnson’s research is focused on predictive toxicology utilizing computational methodology to analyze chemical-biological interactions, model quantitative structure activity relationships, and analyze perturbations in systems biology pathways. These technologies are being applied to solve problems in environmental toxicity (green chemistry initiatives) and side effects associated with human therapeutics.
Through his affiliation with Emiliem, Inc. his research involves novel compounds that are mammalian target of rapamycin (mTOR) pathway inhibitors. mTOR is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. Studies have linked mTOR to several human diseases including cancer, inflammation, diabetes, obesity, cardiovascular diseases and neurological disorders. mTOR is found in 2 structurally and functionally distinct multiprotein complexes termed mTOR complex 1 (mTORC1) and mTORC2. mTORC2, which consists of rictor, mSIN1, mLST8, and mTOR, is activated by insulin/IGF1 and phosphorylates Ser-473 in the hydrophobic motif of Akt/PKB. Recently, mTORC2 in adipose tissue has been suggested to play a central role in controlling whole-body growth. The research at Emiliem involves discovering and developing pathway inhibitors of both mTOR complexes as potential therapeutics in cancer and other proliferative and inflammatory diseases.
Most Recent Publications
Dale E. Johnson and Grace L. Anderson: Green Chemistry and Toxicology. In "Green Chemistry and Engineering: A Pathway to Sustainability". Editors: M. Abraham and A.E. Marteel-Parrish. Wiley & Sons (In Press)
Dale E. Johnson (2012) Predicting drug safety: Next generation solutions. J Drug Metab Toxicol 3 (2) Open Access http://dx.doi.org/10.4172/2157-7609.1000e106
Johnson Dale E, Srinivasan Subha, Bingham Jonathan, and Sudarsanam Sucha. (2012) Translational biology approach to identify causative factors for rare toxicities in humans and animals. Curr Drug Discov Technol 9(1) 77-80.
Harmony Larson, Elena Chan, Sucha Sudarsanam, and Dale E. Johnson. (2012) Biomarkers. In Computational Toxicology Vol II. Chapter 11, Methods in Molecular Biology, Eds. Reisfeld B and Mayeno A.Humana Press, Springer Science, NY, NY. DOI 10.1007/978-1-62703-059-5_11
Dale E. Johnson and Sucha Sudarsanam (2012) Molecular challenges in frontloading toxicity testing of anti-cancer drugs in drug discovery. Encyclopedia of Drug Metabolism and Interactions. Chapter 3. Pp-1-20, Ed. Lyubinov AV, John Wiley & Sons, New York. DOI:10.1002/9780470921920.edm048
Dale E. Johnson (2010) Biotherapeutic first in human dose selection: making use of preclinical markers Expert Rev Clin Pharmacol 3(2) 231-242
Johnson DE, Smith DA, and Park BK (2010) Immunomodulatory Therapies and the risk of Opportunistic Infections Current Opinion Drug Disc Develop 13 (1) 20-22
Elena Chan, Marisela Tan, Jianni Xin, Sucha Sudarsanam, and Dale E. Johnson (2010) Interactions between Traditional Chinese Medicines and Western Therapeutics Current Opinion Drug Disc Develop 13(1) 58-73
Sucha Sudarsanam and Dale E. Johnson (2010) Functional consequences of mTOR inhibition Current Opinion Drug Disc Develop 13(1) 39-48
Johnson DE, Smith DA, and Park BK (2009) Pharmacogenomics and adverse drug reactions; prospective screening for risk identification. Current Opinion Drug Disc Develop 12(1) 27-30
Srinivasan S, Bingham J, and Johnson DE (2009) The ABC’s of Human Alternative Splicing: A Review of ATP-Binding Cassette Transporter Splicing. Current Opinion Drug Disc Develop 12(1) 149-158
Liu W and Johnson DE (2009) Clustering and its application in multi-target prediction. Current Opinion Drug Disc Develop 12(1) 98-107
Chiao S, Romero D, Johnson DE (2009) Current HIV Therapeutics: mechanistic and chemical determinants of toxicity. Current Opinion Drug Disc Develop 12(1) 53-60
Johnson DE, Park BK, and Smith DA (2008) Ethnic variation in drug response: Implications for the development and regulation of drugs. Current Opinion Drug Disc Develop 11(1) 29-31. Dale E. Johnson, Amie D. Rodgers, and Sucha Sudarsanam (2007) Future of Computational Toxicology: Broad Application into Human Disease and Therapeutics. In Computational Toxicology: Risk Assessment For Pharmaceutical and Environmental Chemicals, Ed. Ekins, S, John Wiley & Sons, New York, pp. 725-749.
Johnson DE, Smith DA, and Park BK (2007) Biomarkers: The piece de resistance of innovative medicines. Current Opinion Drug Disc Develop 10(1) 22-24.
Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O’Hara C, Powers DB, Liu G, Grove J, Hevezi P, Cass KM, Watson S, Evangelista F, Powers RA, Finck B, Wills M, Caras I, Fang Y, McDonald D, Johnson D, Murray R, Jeffry U (2006) Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5(6) 273-86.